Taishi Nakamura1, Guangshuo Zhu1, Mark J Ranek1, Kristen Kokkonen-Simon1, Manling Zhang1, Grace E Kim1, Kenichi Tsujita1, David A Kass2. 1. From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD (T.N., G.Z., M.J.R., K.K.-S., M.Z., G.E.K., D.A.K.); and Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan (T.N., K.T.). 2. From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD (T.N., G.Z., M.J.R., K.K.-S., M.Z., G.E.K., D.A.K.); and Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan (T.N., K.T.). dkass@jhmi.edu.
Abstract
BACKGROUND: Stimulation of sGC (soluble guanylate cyclase) or inhibition of PDE5 (phosphodiesterase type 5) activates PKG (protein kinase G)-1α to counteract cardiac hypertrophy and failure. PKG1α acts within localized intracellular domains; however, its oxidation at cysteine 42, linking homomonomers, alters this localization, impairing suppression of pathological cardiac stress. Because PDE5 and sGC reside in separate microdomains, we speculated that PKG1α oxidation might also differentially influence the effects from their pharmacological modulation. METHODS AND RESULTS: Knock-in mice expressing a redox-dead PKG1α (PKG1αC42S) or littermate controls (PKG1αWT) were subjected to transaortic constriction to induce pressure overload and treated with a PDE5 inhibitor (sildenafil), sGC activator (BAY602770 [BAY]), or vehicle. In PKG1αWT controls, sildenafil and BAY similarly enhanced PKG activity and reduced pathological hypertrophy/fibrosis and cardiac dysfunction after transaortic constriction. However, sildenafil failed to protect the heart in PKG1αC42S, unlike BAY, which activated PKG and thereby facilitated protective effects. This corresponded with minimal PDE5 activation in PKG1αC42S exposed to transaortic constriction versus higher activity in controls and little colocalization of PDE5 with PKG1αC42S (versus colocalization with PKG1αWT) in stressed myocytes. CONCLUSIONS: In the stressed heart and myocytes, PKG1α C42-disulfide formation contributes to PDE5 activation. This augments the pathological role of PDE5 and so in turn enhances the therapeutic impact from its inhibition. PKG1α oxidation does not change the benefits from sGC activation. This finding favors the use of sGC activators regardless of PKG1α oxidation and may help guide precision therapy leveraging the cyclic GMP/PKG pathway to treat heart disease.
BACKGROUND: Stimulation of sGC (soluble guanylate cyclase) or inhibition of PDE5 (phosphodiesterase type 5) activates PKG (protein kinase G)-1α to counteract cardiac hypertrophy and failure. PKG1α acts within localized intracellular domains; however, its oxidation at cysteine 42, linking homomonomers, alters this localization, impairing suppression of pathological cardiac stress. Because PDE5 and sGC reside in separate microdomains, we speculated that PKG1α oxidation might also differentially influence the effects from their pharmacological modulation. METHODS AND RESULTS: Knock-in mice expressing a redox-dead PKG1α (PKG1αC42S) or littermate controls (PKG1αWT) were subjected to transaortic constriction to induce pressure overload and treated with a PDE5 inhibitor (sildenafil), sGC activator (BAY602770 [BAY]), or vehicle. In PKG1αWT controls, sildenafil and BAY similarly enhanced PKG activity and reduced pathological hypertrophy/fibrosis and cardiac dysfunction after transaortic constriction. However, sildenafil failed to protect the heart in PKG1αC42S, unlike BAY, which activated PKG and thereby facilitated protective effects. This corresponded with minimal PDE5 activation in PKG1αC42S exposed to transaortic constriction versus higher activity in controls and little colocalization of PDE5 with PKG1αC42S (versus colocalization with PKG1αWT) in stressed myocytes. CONCLUSIONS: In the stressed heart and myocytes, PKG1α C42-disulfide formation contributes to PDE5 activation. This augments the pathological role of PDE5 and so in turn enhances the therapeutic impact from its inhibition. PKG1α oxidation does not change the benefits from sGC activation. This finding favors the use of sGC activators regardless of PKG1α oxidation and may help guide precision therapy leveraging the cyclic GMP/PKG pathway to treat heart disease.
Authors: H Senzaki; C J Smith; G J Juang; T Isoda; S P Mayer; A Ohler; N Paolocci; G F Tomaselli; J M Hare; D A Kass Journal: FASEB J Date: 2001-08 Impact factor: 5.191
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Mihai Gheorghiade; Stephen J Greene; Javed Butler; Gerasimos Filippatos; Carolyn S P Lam; Aldo P Maggioni; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Elisabeth Kraigher-Krainer; Eliana T Samano; Katharina Müller; Lothar Roessig; Burkert Pieske Journal: JAMA Date: 2015-12-01 Impact factor: 56.272
Authors: Ksenia Brusilovskaya; Philipp Königshofer; Daniel Lampach; Adrian Szodl; Paul Supper; David Bauer; Andrea Beer; Judith Stift; Gerald Timelthaler; Georg Oberhuber; Bruno Karl Podesser; Martha Seif; Kerstin Zinober; Nataliya Rohr-Udilova; Michael Trauner; Thomas Reiberger; Philipp Schwabl Journal: United European Gastroenterol J Date: 2020-09-02 Impact factor: 4.623
Authors: Kristen M Kokkonen-Simon; Amir Saberi; Taishi Nakamura; Mark J Ranek; Guangshuo Zhu; Djahida Bedja; Michaela Kuhn; Marc K Halushka; Dong Ik Lee; David A Kass Journal: JCI Insight Date: 2018-08-09
Authors: Daniel A Richards; Mark J Aronovitz; Peiwen Liu; Gregory L Martin; Kelly Tam; Suchita Pande; Richard H Karas; Daniel M Bloomfield; Michael E Mendelsohn; Robert M Blanton Journal: Circ Heart Fail Date: 2021-01-19 Impact factor: 8.790
Authors: Christian U Oeing; Taishi Nakamura; Shi Pan; Sumita Mishra; Brittany L Dunkerly-Eyring; Kristen M Kokkonen-Simon; Brian L Lin; Anna Chen; Guangshuo Zhu; Djahida Bedja; Dong Ik Lee; David A Kass; Mark J Ranek Journal: Circ Res Date: 2020-05-12 Impact factor: 17.367
Authors: Melanie Reinero; Maurice Beghetti; Piergiorgio Tozzi; Ludwig K von Segesser; Michele Samaja; Giuseppina Milano Journal: J Cardiovasc Pharmacol Ther Date: 2021-05-08 Impact factor: 2.457